Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
05 August 2020 - 9:30PM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio™ (nalbuphine ER) to treat serious
neurologically mediated conditions, today announced that management
will participate in a virtual fireside chat, as well as host
virtual investor meetings, at the 2020 BTIG Biotechnology
Conference on August 10, 2020:
Presentation Time: 11:00 a.m. ET
A live webcast of the virtual fireside chat can be accessed by
visiting ‘News & Events’ in the ‘Investors & News’ section
on the Company's website at www.trevitherapeutics.com. An archived
replay of the webcast will also be available for 30 days on the
Company's website following the conference.
The Company’s corporate presentation is posted to its website in
the ‘Investors & News’ section under ‘News & Events’.
About Trevi Therapeutics, Inc.Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of
nalbuphine ER to treat serious neurologically mediated conditions.
Trevi is currently developing nalbuphine ER for the treatment of
chronic pruritus, chronic cough in patients with idiopathic
pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in
patients with Parkinson’s disease. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems. Trevi is currently
conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred
to as the PRISM trial, in patients with severe pruritus associated
with prurigo nodularis.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About HADUVIO Haduvio is an oral extended
release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe. The ĸ- and
µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine’s mechanism of
action also mitigates the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is currently the only opioid approved for marketing that
is not classified as a controlled substance in the United States
and most of Europe. Trevi intends to propose Haduvio as the trade
name for the nalbuphine ER investigational product and will
therefore use that name in Company materials going forward. Haduvio
is an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
Investor ContactChris Seiter, Chief Financial
OfficerTrevi Therapeutics,
Inc.chris.seiter@trevitherapeutics.com203-304-2499
Media ContactRosalia Scampoli
rscampoli@marketcompr.com914-815-1465
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2024 to May 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From May 2023 to May 2024